| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EFTR | Common Stock | Award | +3.98M | 3.98M | Aug 25, 2021 | By U.S. Venture Partners X, L.P. | F1, F2, F3 | |||
| transaction | EFTR | Common Stock | Award | +127K | 127K | Aug 25, 2021 | By USVP X Affliliates, L.P. | F1, F3, F4 | |||
| transaction | EFTR | Common Stock | Award | $6.91M | +691K | +17.35% | $10.00 | 4.67M | Aug 25, 2021 | By U.S. Venture Partners X, L.P. | F3, F5 |
| transaction | EFTR | Common Stock | Award | $221K | +22.1K | +17.35% | $10.00 | 149K | Aug 25, 2021 | By USVP X Affliliates, L.P. | F3, F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EFTR | Earn-out Right | Award | $0 | +587K | $0.00 | 587K | Aug 25, 2021 | Common Stock | 587K | By U.S. Venture Partners X, L.P. | F3, F6 | ||
| transaction | EFTR | Earn-out Right | Award | $0 | +18.8K | $0.00 | 18.8K | Aug 25, 2021 | Common Stock | 18.8K | By USVP X Affliliates, L.P. | F3, F6 |
| Id | Content |
|---|---|
| F1 | On August 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of May 26, 2021 (the "Merger Agreement"), by and among the Issuer (f/k/a Locust Walk Acquisition Corp.), Locust Walk Merger Sub, Inc. ("Merger Sub"), and eFFECTOR Therapeutics, Inc. ("Old eFFECTOR"), Merger Sub merged with and into Old eFFECTOR with Old eFFECTOR surviving as a wholly owned subsidiary of the Issuer (the "Merger"). Upon consummation of the Merger (the "Effective Time"), each issued and outstanding share of common stock of Old eFFECTOR was automatically cancelled and converted into approximately 0.09657 (the "Exchange Ratio") shares of common stock of the Issuer. |
| F2 | The 3,981,940 shares of common stock represents the conversion of 25,015,222 shares of Series A Preferred, 9,197,554 shares of Series B Preferred and 7,020,627 shares of Series C Preferred of Old eFFECTOR into an aggregate of 41,233,403 shares of Old eFFECTOR common stock and the subsequent cancellation and conversion of such shares into shares of common stock of the Issuer in the Merger at the Exchange Ratio. |
| F3 | Presidio Management Group X, LLC ("PMG X") is the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates, L.P. ("AFF X" and together with USVP X, the "USVP X Funds") and has sole voting and dispositive power with respect to the shares held by the USVP X Funds. The Reporting Person is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. The Reporting Person disclaims beneficial ownership of shares held by the USVP X Funds, except to the extent of any proportionate pecuniary interest therein. |
| F4 | The 127,389 shares of common stock represents the conversion of 800,281 shares of Series A Preferred, 294,246 shares of Series B Preferred and 224,604 shares of Series C Preferred of Old eFFECTOR into an aggregate of 1,319,131 shares of Old eFFECTOR common stock and the subsequent cancellation and conversion of such shares into shares of common stock of the Issuer in the Merger at the Exchange Ratio. |
| F5 | Represents shares issued in the private placement which closed concurrently with the Merger. |
| F6 | Each earn-out right represents a contingent right to receive one share of the Issuer's common stock. Pursuant to an "Earn-Out" provision in the Merger Agreement, the earn-out rights vest upon the Issuer's common stock achieving a price per share which equals or exceeds $20.00 over at least 20 trading days out of a 30 consecutive trading day period prior to August 26, 2023. |